Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan

Background. To determine the maximum tolerable infusion rate of rituximab, and investigate the safety and feasibility of rapid infusion of rituximab for patients with CD20 positive B-cell lymphomas (CD20+NHL). Patients and Methods. 18 patients with CD20+NHL were registered. This study had six cohort...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Yokoyama, Masahiro, Terui, Yasuhito, Takeuchi, Kengo, Nara, Eriko, Nakano, Kenji, Ueda, Kyoko, Nishimura, Noriko, Mishima, Yuko, Sakajiri, Sakura, Tsuyama, Naoko, Ozawa, Keiya, Hatake, Kiyohiko
Format: Artigo
Langue:Inglês
Publié: Hindawi Publishing Corporation 2013
Sujets:
Clinical Study
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3649348/
https://ncbi.nlm.nih.gov/pubmed/23691364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2013/863909
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires